Zimmer Biomet to Debut New Z1™ Femoral Hip System and Clinical Data on G7® Acetabular System at 2024 AAHKS Annual Meeting
Company’s Booth Spotlights Comprehensive Hip Portfolio and Enabling Technologies Including OrthoGrid Hip AI® and HAMMR™ Automated Hip Impaction System
WARSAW, Ind., Oct. 28, 2024 /PRNewswire/ — Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced plans for the broad commercial launch of the Z1™ Femoral Hip System (Z1 System) for total hip arthroplasty at the 2024 annual meeting of the American Association of Hip and Knee Surgeons (AAHKS). The highly-anticipated Z1 Femoral Hip System, a triple-taper femoral system, pairs with the Company’s industry-leading G7® Acetabular System to provide surgeons with a versatile, streamlined and efficient total hip arthroplasty solution. At the meeting, being held November 7-10 in Dallas, positive data on the safety and durability of the G7 Acetabular System will be presented during the poster sessions.
“We are excited to share our robust hip portfolio, anchored by our new triple-taper femoral stem, Z1, and our well-established G7 Acetabular System,” said Ivan Tornos, President and Chief Executive Officer of Zimmer Biomet. “Through a series of strategic acquisitions and in-house innovations, we’ve curated a diversified portfolio of hip implant solutions and innovative enabling technologies that provide surgeons with a wide array of options designed to address efficiency, accuracy and customization with a goal to improve overall surgical outcomes for patients.”
The Z1 System is tapered in three planes, designed to provide initial axial and rotational stability, as well as long-term stability across a range of femoral anatomies. The system includes collared and collarless options for cementless applications and offers three distinct neck options to manage a variety of patient anatomies. Offered with a single streamlined instrument tray, the Z1 System minimizes the instrument footprint and reduces processing and sterilization burden.
Dr. Jesse Otero of OrthoCarolina, and Dr. Jonathan Yerasimides of Louisville Hip & Knee Institute, performed the first patient cases using the Z1 System.
“My first experience with the Z1 triple-taper femoral stem with the G7 Acetabular System can be summarized as the easiest and most natural implantation I have experienced,” said Dr. Otero. Dr. Yerasimides added, “Z1 was simple and intuitive to use, and offers significant options and more versatility than earlier stems.”
“Building on the success of our G7 Acetabular System, we delivered the Z1 System to address demand for a versatile and adaptable triple-taper femoral stem that allows surgeons to customize care for a broad range of hip arthroplasty patients,” said Louis Galrao, President, Hips at Zimmer Biomet. “The Z1 and G7 systems are enhanced by our curated suite of enabling technologies, which are designed to complement a variety of surgical approaches and workflows to make AI-, robotic- and mixed reality-powered surgical navigation and guidance accessible and approachable for more surgeons and care teams.”
Earlier this month, Zimmer Biomet further strengthened its hip portfolio with the acquisition of OrthoGrid Systems, Inc. and its multiple FDA-cleared, AI-powered, fluoroscopy-based surgical assistance applications, including OrthoGrid Hip AI®. OrthoGrid Hip AI delivers intuitive and instantaneous intra-operative guidance to assist the surgeon in achieving the desired surgical outcomes for cup positioning and leg length,1 and offset. OrthoGrid Hip AI is the newest addition to Zimmer Biomet’s suite of enabling technologies for hip procedures which include HAMMR™, an adjustable and ergonomic automated impaction device that allows a surgeon to perform a total hip replacement with minimal to no mallet use.
Zimmer Biomet Activities at 2024 AAHKS Annual Meeting
At Booth #1100, Zimmer Biomet will display the Z1 and G7 systems, along with HAMMR, OrthoGrid Hip AI and its mixed reality and robotic technologies for hip procedures. In addition, data from three clinical studies, supported by Zimmer Biomet, will be presented in e-poster sessions*:
- Metal Ion Levels in Patients Undergoing Hip Arthroplasty with the G7® Dual Mobility System (Poster # 228; Lead Author: Krishna R. Tripuraneni, M.D.)
- Short- to Mid-Term Clinical Outcomes and Survivorship of a Porous Plasma-Sprayed Limited Hole Acetabular Shell (Poster # 227; Lead Author: Krishna R. Tripuraneni, M.D.)
- Is Change in Walking Asymmetry Correlated with Changes in Quality of Life in Patients Undergoing Total Joint Arthroplasty? (Poster # 206; Lead Author: Adolph V. Lombardi, Jr., M.D., FACS)
To learn more about Zimmer Biomet’s hip portfolio, including the Z1 Femoral Hip System, visit www.zimmerbiomet.com/hip.
| * Data results from accepted poster presentations are embargoed by AAHKS until Friday, November 8, 2024. Visit https://meeting.aahks.org/ to view the posters. |
About the Company
Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamlessly transform the patient experience through our innovative products and suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence.
With 90+ years of trusted leadership and proven expertise, Zimmer Biomet is positioned to deliver the highest quality solutions to patients and providers. Our legacy continues to come to life today through our progressive culture of evolution and innovation.
For more information about our product portfolio, our operations in 25+ countries and sales in 100+ countries or about joining our team, visit www.zimmerbiomet.com or follow on LinkedIn at www.linkedin.com/company/zimmerbiomet or X / Twitter at www.twitter.com/zimmerbiomet.
Cautionary Statement Regarding Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning Zimmer Biomet’s expectations, plans, prospects, and product and service offerings, including new product launches and potential clinical successes. Such statements are based upon the current beliefs and expectations of management and are subject to significant risks, uncertainties and changes in circumstances that could cause actual outcomes and results to differ materially. For a list and description of some of such risks and uncertainties, see Zimmer Biomet’s periodic reports filed with the U.S. Securities and Exchange Commission (SEC). These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in Zimmer Biomet’s filings with the SEC. Forward-looking statements speak only as of the date they are made, and Zimmer Biomet disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Readers of this news release are cautioned not to rely on these forward-looking statements, since there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary statement is applicable to all forward-looking statements contained in this news release.
References
1. Cardenas JM, Gordon D, Waddell BS, Kitziger KJ, Peters PC Jr, Gladnick BP. Does Artificial Intelligence Outperform Humans Using Fluoroscopic-Assisted Computer Navigation for Total Hip Arthroplasty? Arthroplast Today. 2024 May 27;27:101410. doi: 10.1016/j.artd.2024.101410. PMID: 38840694; PMCID: PMC11150909.
Media
Heather Zoumas-Lubeski
445-248-0577
Investors
David DeMartino
646-531-6115
Zach Weiner
908-591-6955
SOURCE Zimmer Biomet Holdings, Inc.
